Aflibercept

Therapeutic indications

Aflibercept is indicated for:

Metastatic colorectal cancer (MCRC)

Population group: both men and women, only adults (18 years old or older)

Aflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

4 mg/kg once every 2 weeks

Neovascular (wet) age-related macular degeneration (AMD)

Population group: both men and women, only adults (18 years old or older)

Exudative age-related macular degeneration

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month

Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

Population group: both men and women, only adults (18 years old or older)

Thrombosis of retinal vein and additionally

Macular retinal edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month

Visual impairment due to diabetic macular oedema (DME)

Population group: both men and women, only adults (18 years old or older)

Diabetic macular edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month

Visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Population group: both men and women, only adults (18 years old or older)

mCNV - myopic choroidal neovascularisation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month

Contraindications

Aflibercept is contraindicated in the following cases:

Ocular, periocular, intraocular inflammation or infection

Ophthalmitis

< Previous: Overview

Next: Precautions >

Aflibercept

Therapeutic indications

Metastatic colorectal cancer (MCRC)

4 mg/kg once every 2 weeks

Neovascular (wet) age-related macular degeneration (AMD)

2 mg once every month

Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

2 mg once every month

Visual impairment due to diabetic macular oedema (DME)

2 mg once every month

Visual impairment due to myopic choroidal neovascularisation (myopic CNV)

2 mg once every month

Contraindications

Ocular, periocular, intraocular inflammation or infection

Get recommendations

Related medicines